Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Intercept Pharmaceuticals Clear all
Terminated Phase 3 Interventional Results available

To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate

NCT06488911
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
FDC tablet (OCA 5 mg + BZF 400 mg SR)
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Coronado, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 28, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)

NCT02177136
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
Obeticholic Acid (OCA), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
33
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 28, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

NCT01865812
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Obeticholic Acid
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Sep 28, 2026, 11:46 PM EDT
Withdrawn No phase listed Observational

A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients

NCT05293938
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Obeticholic Acid 5 MG, Obeticholic Acid 10 MG, Standard of Care: UDCA
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 28, 2026, 11:46 PM EDT
Terminated Phase 3 Interventional Results available

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

NCT02548351
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
Obeticholic Acid, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
175
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 28, 2026, 11:46 PM EDT
Terminated Phase 2 Interventional Results available

Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

NCT00550862
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
INT-747, Ursodeoxycholic Acid (URSO), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
13
States / cities
Gainesville, Florida • Miami, Florida • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Sep 28, 2026, 11:46 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)

NCT02039219
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Placebo, 10 mg Obeticholic Acid (OCA)
Drug
Lead sponsor
Naga P. Chalasani
Other
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Indianapolis, Indiana • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 28, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

Study of INT-747 in Patients With Diabetes and Presumed NAFLD

NCT00501592
View directory record Official record
Conditions
Diabetes Mellitus, Type II, Fatty Liver
Interventions
INT-747, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Chula Vista, California • San Diego, California • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Sep 28, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

NCT03439254
View directory record Official record
Conditions
Compensated Cirrhosis, Nonalcoholic Steatohepatitis
Interventions
Obeticholic acid (10 mg), Obeticholic acid (10 mg to 25 mg), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
120
States / cities
Dothan, Alabama • Madison, Alabama • Chandler, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 28, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

NCT05239468
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Birmingham, Alabama • Coronado, California • Mission Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 28, 2026, 11:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)

NCT01933503
View directory record Official record
Conditions
Healthy
Interventions
OCA 5 mg, OCA 10 mg, OCA 25 mg
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Sep 28, 2026, 11:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling

NCT02654236
View directory record Official record
Conditions
Alcohol Consumption
Interventions
Placebo, 10 mg Obeticholic Acid (OCA)
Drug
Lead sponsor
Suthat Liangpunsakul
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 28, 2026, 11:46 PM EDT
Terminated Phase 4 Interventional Results available

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

NCT03633227
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
Obeticholic Acid (OCA), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
Rialto, California • Sacramento, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2022 · Synced Sep 28, 2026, 11:46 PM EDT
Terminated Phase 4 Interventional Results available

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis

NCT02308111
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
Obeticholic Acid (OCA), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
43
States / cities
Phoenix, Arizona • Los Angeles, California • Rialto, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Sep 28, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

NCT00570765
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
Placebo, Obeticholic Acid (OCA)
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
4
States / cities
Detroit, Michigan • Houston, Texas • Richmond, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 28, 2026, 11:46 PM EDT
Active, not recruiting No phase listed Observational

LITMUS Imaging Study

NCT05479721
View directory record Official record
Conditions
NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver
Interventions
Not listed
Lead sponsor
University of Oxford
Other
Eligibility
18 Years to 100 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 28, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)

NCT02633956
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Obeticholic Acid, Atorvastatin, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
22
States / cities
Phoenix, Arizona • La Jolla, California • Rialto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Sep 28, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

NCT01473524
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Obeticholic Acid (OCA), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
15
States / cities
Sacramento, California • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Sep 28, 2026, 11:46 PM EDT
Terminated Phase 2 Interventional

FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study

NCT05639543
View directory record Official record
Conditions
Alcohol Associated Hepatitis
Interventions
INT-787, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Fresno, California • Palo Alto, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 28, 2026, 11:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Food on Pharmacokinetics of Obeticholic Acid (OCA)

NCT01914562
View directory record Official record
Conditions
Healthy
Interventions
OCA 10 mg, OCA 25 mg
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Sep 28, 2026, 11:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Hepatic Impairment Trial of Obeticholic Acid

NCT01904539
View directory record Official record
Conditions
Hepatic Impairment
Interventions
obeticholic acid 10 mg
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Sep 28, 2026, 11:46 PM EDT
Completed No phase listed Observational Results available

Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients

NCT05292872
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Not listed
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
4,577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Sep 28, 2026, 11:46 PM EDT